Theratechnologies Inc. Stock

Equities

TH

CA88338H7040

Pharmaceuticals

Market Closed - Toronto S.E. 03:55:37 2024-05-27 pm EDT 5-day change 1st Jan Change
1.77 CAD -0.56% Intraday chart for Theratechnologies Inc. 0.00% -17.29%
Sales 2024 * 120M 87.77M Sales 2025 * 132M 96.65M Capitalization 81.85M 60.04M
Net income 2024 * -4M -2.93M Net income 2025 * -6M -4.4M EV / Sales 2024 * 0.68 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.62 x
P/E ratio 2024 *
-15.5 x
P/E ratio 2025 *
-14.8 x
Employees 103
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.58%
More Fundamentals * Assessed data
Dynamic Chart
Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate MT
Theratechnologies Brief: Says Sudocetaxel Zendusortide ASCO 2024 Presentation "Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors" MT
Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors CI
Transcript : Theratechnologies Inc. - Shareholder/Analyst Call
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision MT
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug MT
Transcript : Theratechnologies Inc., Q1 2024 Earnings Call, Apr 10, 2024
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024 CI
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level MT
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million MT
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA MT
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024 CI
North American Morning Briefing : Traders Await -2- DJ
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform CI
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee CI
More news

Latest transcript on Theratechnologies Inc.

1 day-0.56%
1 month-1.12%
3 months-15.31%
6 months-12.38%
Current year-17.29%
More quotes
1 week
1.71
Extreme 1.71
1.92
1 month
1.61
Extreme 1.61
1.92
Current year
1.61
Extreme 1.61
3.43
1 year
1.22
Extreme 1.22
5.56
3 years
1.22
Extreme 1.22
22.44
5 years
1.22
Extreme 1.22
31.92
10 years
1.22
Extreme 1.22
59.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 20-04-05
Director of Finance/CFO 57 16-02-23
Chief Tech/Sci/R&D Officer 61 06-12-31
Members of the board TitleAgeSince
Director/Board Member 56 20-10-15
Chairman 67 21-06-22
Director/Board Member 68 17-05-15
More insiders
Date Price Change Volume
24-05-27 1.77 -0.56% 2,730
24-05-24 1.78 +4.09% 13,684
24-05-23 1.71 -2.84% 12,200
24-05-22 1.76 -0.56% 7,511

Delayed Quote Toronto S.E., May 27, 2024 at 03:55 pm EDT

More quotes
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.78 CAD
Average target price
8 CAD
Spread / Average Target
+349.44%
Consensus